Literature DB >> 22798338

Risk factors for impaired lung function after pulmonary metastasectomy: a prospective observational study of 117 cases.

Stefan Welter1, Danjouma Cheufou, Christian Ketscher, Kaid Darwiche, Frank Maletzki, Georgios Stamatis.   

Abstract

OBJECTIVES: The prediction of postoperative preserved pulmonary function is essential for ascertaining the functional operability of pulmonary metastasectomy candidates. Formulae to predict pulmonary function after metastasectomy have not yet been described. This study was undertaken to provide data about the functional loss after a pulmonary metastasectomy, which often includes non-anatomical resections or combinations with anatomical resections.
METHODS: Pulmonary function tests were performed preoperatively, postoperatively and 3 months after a pulmonary metastasectomy, and the factors potentially influencing the functional outcome were prospectively collected in a database. The functional loss was calculated as the difference in the values between the follow-up visit and the preoperative values, and the influencing factors were tested using the Mann-Whitney test.
RESULTS: A total of 162 patients were prospectively included in the study and 117 completed the study protocol with a follow-up evaluation after a mean of 3.4 months. Of these, 33 patients had bilateral resections, 30 interventions were repeated resections and adhesions were removed in 46. The greatest lung resection performed was a lobectomy in 13, with segmentectomy in 27 and wedge resection in 77 patients. The mean overall functional loss was: forced vital capacity -9.2%, total lung capacity -8.8%, forced expiratory volume in 1 s -10.8% and diffusion capacity for carbon monoxide (DLCO) -9.7%, whereas the diffusion coefficient (KCO) and pO(2) remained unchanged after 3 months. This functional loss was significant (P < 0.001) for all the parameters mentioned. The two factors were inversely found to influence the functional outcome: bilateral resection reduced spirometry values (P < 0.01), postoperative chemotherapy reduced DLCO (P = 0.011) and KCO (P = 0.029).
CONCLUSIONS: A pulmonary metastasectomy leads to a significant loss of pulmonary function after 3 months in an average patient collective. The most important factors for deteriorating lung function are a bilateral operation and postoperative chemotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 22798338     DOI: 10.1093/ejcts/ezs293

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  History and present status of pulmonary metastasectomy in colorectal cancer.

Authors:  Tom Treasure; Mišel Milošević; Francesca Fiorentino; Joachim Pfannschmidt
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Role of segmentectomy for pulmonary metastases.

Authors:  Mark F Berry
Journal:  Ann Cardiothorac Surg       Date:  2014-03

Review 3.  Management of Sarcoma Metastases to the Lung.

Authors:  Christopher S Digesu; Ory Wiesel; Ara A Vaporciyan; Yolonda L Colson
Journal:  Surg Oncol Clin N Am       Date:  2016-10       Impact factor: 3.495

4.  Pulmonary laser-assisted metastasectomy is associated with prolonged survival in patients with colorectal cancer.

Authors:  Isabelle Moneke; Friederike Funcke; Severin Schmid; Thomas Osei-Agyemang; Bernward Passlick
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 5.  Impact of the extent of lung resection on postoperative outcomes of pulmonary metastasectomy for colorectal cancer metastases: an exploratory systematic review.

Authors:  Elena Prisciandaro; Laurens J Ceulemans; Dirk E Van Raemdonck; Herbert Decaluwé; Paul De Leyn; Luca Bertolaccini
Journal:  J Thorac Dis       Date:  2022-07       Impact factor: 3.005

6.  Pulmonary metastasectomy for sarcoma-Essen experience.

Authors:  Dumitrita Alina Gafencu; Stefan Welter; Danjouma Housmanou Cheufou; Till Ploenes; Georgios Stamatis; Martin Stuschke; Dirk Theegarten; Christian Taube; Sebastian Bauer; Clemens Aigner
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.